For the quarter ending 2026-03-31, FULC had -$147,272K decrease in cash & cash equivalents over the period. -$18,758K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,891 | -20,334 | -19,595 | -34,951 |
| Depreciation expense | 338 | 347 | 346 | 697 |
| Stock-based compensation expense | 3,860 | 3,066 | 3,360 | 6,042 |
| Net accretion of discounts on marketable securities | 767 | 383 | 586 | 1,984 |
| Unbilled accounts receivable | 0 | 0 | 0 | -2,096 |
| Prepaid expenses and other current assets | 179 | -44 | -44 | -1,544 |
| Operating lease assets and liabilities | 195 | 195 | 195 | 353 |
| Other assets | 8 | 529 | -3 | 2 |
| Accounts payable | 858 | -1,105 | 946 | 587 |
| Accrued expenses and other liabilities | -3,766 | 2,291 | 1,487 | -2,753 |
| Net cash used in operating activities | -18,750 | -16,798 | -14,190 | -29,077 |
| Purchases of marketable securities | 155,337 | 26,137 | 17,293 | 136,790 |
| Maturities of marketable securities | 27,135 | 25,247 | 35,995 | 150,011 |
| Purchases of property and equipment | 8 | 159 | 90 | 65 |
| Net cash used in investing activities | -128,210 | -1,049 | 18,612 | 13,156 |
| Proceeds from issuance of common stock and pre-funded warrants in connection with public offerings, net of issuance costs | - | 164,500 | - | - |
| Payments of offering costs associated with the issuance of common stock and pre-funded warrants | 333 | - | - | - |
| Proceeds from issuance of common stock under benefit plans, net | 21 | 3,802 | 64 | 301 |
| Net cash used in financing activities | -312 | 168,302 | 64 | 301 |
| Net decrease in cash, cash equivalents and restricted cash | -147,272 | 150,455 | 4,486 | -15,620 |
| Cash, cash equivalents, and restricted cash, beginning of period | 198,734 | 48,279 | 59,413 | - |
| Cash, cash equivalents, and restricted cash, end of period | 51,462 | 198,734 | 48,279 | - |
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)